Ana‐Maria Vlădăreanu

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 44 citations

Hematological Malignancy, Oncology, Transplantation +8

<i><scp>TERT</scp></i> rs2736100 A&gt;C <scp>SNP</scp> and <i><scp>JAK</scp>2</i> 46/1 haplotype significantly contribute to the occurrence of <i><scp>JAK</scp>2</i> V617F and <i><scp>CALR</scp></i> mutated myeloproliferative neoplasms – a multicentric study on 529 patients

Adrian P. Trifa, Claudia Bănescu, Mihaela Tevet et al. · British Journal of Haematology · 2016 · 34 citations

LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation

Andrei Coliţă, Anca Coliță, Horia Bumbea et al. · Frontiers in Oncology · 2019 · 30 citations · Full text

<i>MECOM</i>, <i>HBS1L‐MYB</i>, <i>THRB‐RARB, JAK2</i>, and <i>TERT</i> polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients

Adrian P. Trifa, Claudia Bănescu, Anca Bojan et al. · American Journal of Hematology · 2017 · 29 citations · Full text

3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin’s lymphoma

Diana Mihalcea, Maria Florescu, Ramona Bruja et al. · Scientific Reports · 2020 · 22 citations · Full text